Issue Rethinking the Ethical Corporate Vision

Current Issue: Q1 2019

The Business Development Issue

Rethinking the Ethical Corporate Vision

Our first quarter issue features leading insights from key opinion leaders on a variety of topics concerning business development in the pharma and biopharma outsourcing sector.

Also In This Issue

Form-Fill-Seal

Investing in Form-Fill-Seal Technology

Extensive process understanding is required to ensure the consistent manufacture of high-quality sterile parenteral products. At Grifols, our use of state-of-the-art automated aseptic processing systems, including form-fill-seal (FFS) technology, ensures control with minimal human intervention. What is Form-Fill-Seal Technology? The form-fill-seal process involves the use of a single piece of equipment to form a plastic […]

Outsourcing

Aligning the Outsourcing Relationship

As outsourcing to pharmaceutical contract service providers increases, aligning the goals of sponsors and suppliers has become increasingly important. Servier, through its contract manufacturing division, is responding to this market demand by prioritizing strategic partnerships, our service offering, quality and compliance. Alignment Considerations One of the ways in which drug companies are seeking to boost […]

Commercialization

Adjusting Internal Structure to Better Meet Demands of Unmet Business

Founded initially as a formulation development company, UPM has continuously invested in expanding capabilities to support the rapid commercialization of solid and semisolid drug products. With our technical expertise and rich history in successful scale-up and technology transfer, we ensure the rapid commercialization of highly effective, customized and innovative products. Expanding Capabilities The ongoing provision […]

Formulation

Developing and Characterizing DPI Formulations for Biologics

While biologic drugs offer unique new opportunities for treatment, they present challenges associated with patient compliance via the parenteral delivery route. Alternative methods of administration would make these critical medicines more convenient for patients. Inhaled biologics is one such alternative that can provide both targeted delivery to the lungs and systemic delivery. Why Inhalation Delivery […]

Nice Insight Overview

Pharma Tackles the Big Issues

NICE INSIGHT OVERVIEW: From Compliance to Sustainability and Beyond Ethical concerns are a key component of corporate missions and positioning. In addition to ensuring the quality, safety and efficacy of their products, pharmaceutical companies pursue various initiatives to improve all aspects of their operations, from implementing sustainable manufacturing practices to collaborating with nonprofits and developing […]

Supply Chain Solutions

Integrated Clinical Packaging, Warehousing and Transport Services Supporting Pharma and Biopharma

INDUSTRY LEADER INSIGHT: Supply Chain Solutions Managing clinical trials is complex and challenging. Ensuring that the right clinical trial materials and finished pharmaceutical products reach patients at the right time and in excellent condition is just one of the intricate tasks involved. Maintaining temperature-controlled shipment of biologic samples across borders is another. Yourway offers the […]

Investment in Innovation

How Agile Investment Drives Innovation

As objectives and capacity become increasingly complex, many pharmaceutical companies are turning to outsourcing partners to provide innovation in manufacturing. A CDMO that provides products as well as services, from development to commercialization, and that possesses the agility to quickly adapt and invest in innovative technology, can serve as a single-source provider capable of meeting […]

QPCR

Digital Droplet PCR for Viral Vector Analysis

Polymerase chain reaction (PCR) is an essential tool for the analysis of therapeutic viral vectors used in cell and gene therapies. Digital droplet PCR (ddPCR) offers significant advantages over other qPCR methods, allowing for absolute, rather than relative, quantification of the target DNA molecules present in a sample, which is critical to a range of […]

Viral Vectors

Preclinical to Nearly Commercial Virus and Viral Vector Manufacturing

As gene and modified cell therapies advance rapidly through the clinic to commercialization, drug developers are looking to secure commercial production capacity. Novasep has combined its extensive experience in viral vector manufacturing with significant investments in expanded drug substance and fill-finish capabilities. Rapid Growth in Demand for Viral Vectors The global market for viral vector […]

HPAPI

Investing in the Future of Potent Compounds

Shifting needs in the pharmaceutical market are driving a demand for the manufacture of highly potent active pharmaceutical ingredients at a variety of scales. By building a new potent unit that expands our potent compound production capabilities from small to commercial scale, Seqens is expanding the scope of our contract manufacturing services. Potent Market Growth […]

Past Issues

View all Past Issues

The Executive Issue

View Issue »

Issue #1 | Volume #6 | Q1 2020

Future Pharma Partner Models

View Issue »

Issue #3 | Volume #3 | Q3 2017

The Advanced Therapeutics Issue

View Issue »

Issue #2 | Volume #5 | Q2 2019

The Business Development Issue

View Issue »

Issue #1 | Volume #5 | Q1 2019